As announced in connection with the publication of the 2006 full-year results,
Novozymes will change its revenue reporting in 2007. With the increasing
activities within solutions for the biopharmaceutical industry, it has been
decided to report these activities as a separate business area, creating more
revenue transparency.
The new business area is named Biopharmaceutical Ingredients, and will comprise
the activities related to Novozymes Delta, Novozymes GroPep, Novozymes
Biopharma and also the research project within recombinant human serum albumin
(rHSA).
Historically these revenue streams have been reported as other technical
enzymes. Table 1 below discloses a breakdown of 2005 and 2006 quarterly sales
of other technical enzymes in the old reporting and the new reporting split
between technical enzymes and biopharmaceutical ingredients.
Table 1.:
Download PDF for the full stock exchange announcement
